Company: Kezar Life Sciences, Inc.
Kaskela Law LLC is investigating Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (Nasdaq: KZR) on behalf of the Company’s investors. The investigation seeks to determine whether Kezar violated the federal securities laws in connection with and following the Company’s initial public offering (“IPO”) of securities.
In June 2018, Kezar completed its IPO, selling over 5.75 million shares of common stock to investors at $15.00 per share, for gross proceeds of over $86 million.
On May 28, 2019, Kezar reported disappointing preliminary data from the first two cohorts of an open-label dose escalation trial of the Company’s KZR-616 in patients with systemic lupus erythematosus.
Following this news, shares of the Company’s common stock fell $6.99 per share, or over 41% in value, to close on May 28, 2019 at $9.90 per share.
Investors who purchased shares of Kezar’s common stock and suffered an investment loss are encouraged to contact Kaskela Law LLC at (888) 715–1740, or by completing the information form on this page, to receive additional information about this investigation and their legal rights and options.